News Sentiment

GH sentiment intelligence

Guardant Health Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 53 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Diagnostics & Research Read-through group
Latest close 160.05 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-4.7% over one week, +21.6% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

How Expanded Coverage for Guardant’s Shield Test Will Impact UnitedHealth Group (UNH) Investors

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction -4.7% Price reacting lower
Trend fit Trend active 21.6% over four weeks
Fair value 208.4% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 34
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 10
Simply Wall Street 6
Market source 6
simplywall.st 6
TradingView 4
Investing.com 4
Moomoo 3
GuruFocus 1

Event Lens

What the news is about

Classified themes
Market update 29
Analyst action 10
Earnings 8
Deals and strategy 2
Regulatory and legal 2
Balance sheet 1
Macro sensitivity 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 53
Simply Wall Street Direct company coverage

How Expanded Coverage for Guardant’s Shield Test Will Impact UnitedHealth Group (UNH) Investors

UnitedHealth Group's decision to cover Guardant Health's Shield blood test for colorectal cancer screening for roughly 40 million members over 45 aligns with its focus on preventive care. While this move supports UnitedHealth's long-term investment narrative through innovation an

Tone
Positive 65/100
Event
Market update
Published
15 Jul 2026 05:11
Source
Simply Wall Street
GuruFocus Direct company coverage

GH Maintained by Canaccord Genuity -- Price Target Raised to $20

Canaccord Genuity has maintained a "Buy" rating for Guardant Health (GH) and raised its price target from $135 to $205, reflecting strong confidence in the company's future performance. Despite this positive analyst outlook and significant growth potential, Guardant Health's stoc

Tone
Neutral 50/100
Event
Analyst action
Published
14 Jul 2026 14:16
Source
GuruFocus
Simply Wall Street Direct company coverage

Guardant Health (GH) Expands Shield Test Access in India, But What Does It Reveal About Its Growth Strategy?

Guardant Health (GH) is expanding access to its Shield Multi-Cancer Detection blood test in India through an agreement with Zydus Lifesciences and Apollo Hospitals. This move into a large healthcare market aims to broaden non-invasive cancer screening access and is part of Guarda

Tone
Positive 64/100
Event
Market update
Published
14 Jul 2026 11:11
Source
Simply Wall Street
The Globe and Mail Direct company coverage

Guardant Health (GH) Receives a Buy from Bank of America Securities

Bank of America Securities reiterated a Buy rating for Guardant Health (GH) with a price target of $190.00. This recommendation comes despite a negative corporate insider sentiment, with more insiders selling shares recently. Guardant Health reported a quarterly revenue of $301.6

Tone
Positive 72/100
Event
Analyst action
Published
14 Jul 2026 10:11
Source
The Globe and Mail
Simply Wall Street Direct company coverage

Guardant Health (GH) Expands Shield In India On Valuation Views Staying Closely Split

Guardant Health (GH) recently announced partnerships with Zydus Lifesciences and Apollo Hospitals to launch its Shield Multi Cancer Detection blood test in India. The stock has seen significant momentum, but valuation views are split, with some analysts considering it slightly ov

Tone
Neutral 50/100
Event
Market update
Published
12 Jul 2026 19:40
Source
Simply Wall Street
Moomoo Direct company coverage

Morgan Stanley Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $175

Morgan Stanley has reiterated its "Buy" rating on Guardant Health (GH.US) and increased its price target to $175. This positive outlook suggests continued confidence from the financial institution in the company's growth prospects. The raised target price indicates a belief in po

Tone
Positive 74/100
Event
Analyst action
Published
10 Jul 2026 05:10
Source
Moomoo
Moomoo Direct company coverage

Press Release: Guardant Health to Report Second Quarter 2026 Financial Results on July 30, 2026

Guardant Health (NASDAQ: GH) will release its second quarter 2026 financial results after market close on Thursday, July 30, 2026. The company will also host a conference call and webcast to discuss the results and provide a business update at 4:30 PM ET / 1:30 PM PT on the same

Tone
Neutral 50/100
Event
Earnings
Published
09 Jul 2026 20:51
Source
Moomoo
Simply Wall Street Direct company coverage

Guardant Health (GH) Stock May Be Fully Priced As Shield Coverage Expands

Guardant Health (GH) has seen a strong 3-year return of 313.6%. While a Discounted Cash Flow (DCF) model suggests the stock is undervalued by 16.1% at around $186 per share, market-based multiples, particularly the P/S ratio of 19.2x (compared to an industry average of 1.5x), ind

Tone
Neutral 50/100
Event
Balance sheet
Published
09 Jul 2026 19:51
Source
Simply Wall Street
Stock Titan Direct company coverage

Guardant Health sets July 30 call for Q2 2026 results

Guardant Health (Nasdaq: GH) announced it will report its second-quarter 2026 financial results after market close on Thursday, July 30, 2026. The company will host a conference call and webcast on the same day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. The webcast will

Tone
Neutral 50/100
Event
Earnings
Published
09 Jul 2026 17:11
Source
Stock Titan
TradingView Direct company coverage

Guardant Health, Inc. Stock 12‑Month Price Target Raised to $161.13, Implies 3% Upside

Guardant Health, Inc. (GH) has seen its average 12-month price target raised to $161.13 by 23 analysts, up from $159.17, implying a 3% potential upside from its July 8 closing price. The consensus rating for GH remains a "Buy" among 29 analysts, with 25 recommending Buy, 2 Hold,

Tone
Positive 70/100
Event
Analyst action
Published
09 Jul 2026 13:41
Source
TradingView
Moomoo Direct company coverage

Guardant Health Slides as Investors Appear to Take Profits After Recent Rally

This article analyzes Guardant Health's stock performance, noting a recent decline likely due to profit-taking after a rally. It will detail the company's financial health, analyst forecasts, and various metrics to provide context for investors. The report aims to offer a compreh

Tone
Negative 32/100
Event
Analyst action
Published
08 Jul 2026 21:41
Source
Moomoo
TradingView Direct company coverage

ETFs Investing in Guardant Health, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold Guardant Health, Inc. stocks, providing key financial metrics for each. The data includes market value, weight, issuer, management style, expense ratio, assets under management (AUM), price, and 3-year NAV total re

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 12:12
Source
TradingView
Simply Wall Street Direct company coverage

How Investors May Respond To UnitedHealth Group (UNH) Covering Guardant’s Shield Blood Test For Colon Cancer

UnitedHealth Group has announced coverage for Guardant Health's Shield blood test for colorectal cancer screening for eligible members, making it the first major commercial insurer to do so. While this move strengthens UnitedHealth's preventive care focus, the article suggests it

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 07:12
Source
Simply Wall Street
TradingView Direct company coverage

Guardant Health, Inc. Stock 12‑Month Price Target Raised to $156.35, Implies 7% Downside

Analyst estimates for Guardant Health, Inc. (GH) show an average 12-month price target increase from $153.96 to $156.35, implying a potential 7% downside from the current closing price. Despite this, the consensus rating from 29 analysts remains "Buy," with a majority recommendin

Tone
Negative 38/100
Event
Analyst action
Published
06 Jul 2026 16:40
Source
TradingView
Investing.com Direct company coverage

Guardant Health stock hits 52-week high at $172.67

Guardant Health Inc. (GH) stock recently hit a 52-week high of $172.67, with a year-over-year total return of 232.63%. Despite its robust performance and 39.56% revenue growth, InvestingPro analysis suggests the stock is overvalued and potentially overbought. The company also rec

Tone
Positive 72/100
Event
Earnings
Published
06 Jul 2026 15:40
Source
Investing.com
Seeking Alpha Direct company coverage

Guardant Health: Great Execution, But At An Excessive Premium (NASDAQ:GH)

Guardant Health (GH) is seeing increased credibility for its Shield product, supported by Quest access and expanded coverage, alongside a strong oncology franchise. While the company's execution is strong and the stock has risen sharply, the author believes the current valuation

Tone
Negative 41/100
Event
Market update
Published
06 Jul 2026 10:15
Source
Seeking Alpha
Simply Wall Street Direct company coverage

Guardant Health (GH) Is Up 12.6% After India Shield Cancer Test Deal And UnitedHealth Coverage Expansion

Guardant Health (GH) recently saw a 12.6% stock increase following two significant developments: an exclusive deal with Zydus Lifesciences to bring its Shield Multi-Cancer Detection blood test to India, and expanded coverage for the Shield test through UnitedHealth. These agreeme

Tone
Neutral 50/100
Event
Deals and strategy
Published
06 Jul 2026 03:10
Source
Simply Wall Street
TheStreet Direct company coverage

Guardant Health stock surges on colon cancer blood test news

Guardant Health's stock surged after UnitedHealth Group agreed to cover its Shield blood test for colon cancer as a first-line screening option for millions of members. This decision led Bernstein SocGen Group to raise its price target for Guardant Health to $200, highlighting a

Tone
Positive 72/100
Event
Analyst action
Published
05 Jul 2026 15:39
Source
TheStreet
Stock Titan Direct company coverage

Guardant Health (GH) CPO logs RSU vesting and $170.77 tax-withholding share transfer

Guardant Health's Chief People Officer, Terilyn J. Monroe, reported the vesting of 4,020 restricted stock units (RSUs) on July 1, 2026. The company withheld 2,099 shares at $170.77 per share to cover tax obligations. Following these transactions, Ms. Monroe retains a significant

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 13:40
Source
Stock Titan
Stock Titan Direct company coverage

Guardant Health (GH) CLO exercises RSUs as shares withheld for taxes

Guardant Health's Chief Legal Officer, John G. Saia, had 7,063 restricted stock units (RSUs) vest, converting into common stock on July 1, 2026. The company withheld 3,707 shares, valued at $170.77 per share, to cover tax obligations related to this vesting event. This transactio

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 02:09
Source
Stock Titan
Stock Titan Direct company coverage

Guardant Health (GH) director converts 155 RSUs into common shares

Guardant Health director Steve E. Krognes converted 155 Restricted Stock Units (RSUs) into common shares on June 30, 2026. This transaction represents a compensation-related vesting event and not an open-market purchase or sale. After the conversion, Mr. Krognes directly holds 14

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 22:12
Source
Stock Titan
Stock Titan Direct company coverage

Guardant Health (GH) CCO receives 7,414 shares from RSU vesting and tax withholding

Guardant Health's Chief Commercial Officer, Chris Freeman, received 7,414 shares through the vesting of restricted stock units (RSUs) on July 1, 2026. This transaction involved the conversion of RSU awards into common stock, with 3,141 shares withheld by the company to cover tax

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 22:12
Source
Stock Titan
Investing.com Direct company coverage

Guardant Health stock rating reiterated at Buy by TD Cowen on UnitedHealth coverage

TD Cowen has reiterated a Buy rating and a $127.00 price target for Guardant Health (NASDAQ:GH) following UnitedHealth's decision to cover the Shield colorectal cancer screening test. This coverage, effective August 1, 2026, for average-risk individuals aged 45-85, is expected to

Tone
Positive 73/100
Event
Analyst action
Published
02 Jul 2026 17:12
Source
Investing.com